HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
PTCT
PTC Therapeutics Inc
Healthcare Biotechnology · New Jersey, USA · Reports in usd
Market Cap: $5.64B
Market Cap
$5.64B
Enterprise Val
$4.11B
P/E Ratio
-146.98
P/B Ratio
-34.12
Trailing PEG (1Y)
0.66
As Of
Jul 30, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value-$165.4M
Gross Margin94.47%
Profit Margin94.47%
Return on Equity21.72%
Return on Assets-1.32%
Current Ratio3.39
Debt/Equity-4.21
LT Debt/Equity-3.77
Revenue Per Share4.35

Income Statement

Jun 30, 2026
Revenue$360.5M
Cost of Revenue$19.9M
Gross Profit$340.6M
R&D$99.2M
SG&A$80.6M
Operating Expenses$191.6M
Operating Income$149.0M
Interest Expense$48.5M
Tax Expense$14.0M
Net Income$83.5M
EPS (Basic)$1.01
EPS (Diluted)$0.92
EBIT$146.0M
EBITDA$163.7M
Consolidated Income$83.5M
Non-Controlling Interests$0.00

Balance Sheet

Jun 30, 2026
Cash & Equivalents$1.05B
Accounts Receivable$239.0M
Inventory$91.4M
Current Assets$2.62B
LT Investments$0.00
Property, Plant & Equipment$126.3M
Intangibles$485.3M
Non-Current Assets$633.1M
Total Assets$3.25B
Accounts Payable$382.2M
Current Debt$73.4M
Current Liabilities$771.1M
LT Debt$623.1M
Non-Current Liabilities$2.64B
Total Liabilities$3.42B
Total Debt$696.5M
Retained Earnings-$2.88B
Shareholder Equity-$165.4M
Shares Outstanding82,949,338

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow$129.1M
Investing Cash Flow-$122.6M
Financing Cash Flow$211.9M
CapEx-$2.2M
Free Cash Flow$126.9M
Depreciation & Amort.$17.7M
Stock-Based Comp$23.3M
Acquisitions / Disposals-$5.0M
Investment Activity-$115.4M
Debt Issued/Repaid$209.2M
Equity Issued/Repaid$16.4M
Dividends Paid$0.00
Net Change in Cash$215.9M
Data cached · Meta live · Daily live · Statements live · TTL 24h